Synonym
BT44; BT-44; BT 44
IUPAC/Chemical Name
(4-(5-((3,4-Dihydroisoquinolin-2(1H)-yl)sulfonyl)-2-methoxyphenyl)piperazin-1-yl)(4-fluoro-2-(trifluoromethyl)phenyl)methanone
InChi Key
MFQBJWVTKPJNEP-UHFFFAOYSA-N
InChi Code
InChI=1S/C28H27F4N3O4S/c1-39-26-9-7-22(40(37,38)35-11-10-19-4-2-3-5-20(19)18-35)17-25(26)33-12-14-34(15-13-33)27(36)23-8-6-21(29)16-24(23)28(30,31)32/h2-9,16-17H,10-15,18H2,1H3
SMILES Code
O=C(N1CCN(C2=CC(S(=O)(N3CC4=C(C=CC=C4)CC3)=O)=CC=C2OC)CC1)C5=CC=C(F)C=C5C(F)(F)F
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
577.59
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Sverchinsky DV, Nikotina AD, Komarova EY, Mikhaylova ER, Aksenov ND, Lazarev VF, Mitkevich VA, Suezov R, Druzhilovskiy DS, Poroikov VV, Margulis BA, Guzhova IV. Etoposide-Induced Apoptosis in Cancer Cells Can Be Reinforced by an Uncoupled Link between Hsp70 and Caspase-3. Int J Mol Sci. 2018 Aug 25;19(9):2519. doi: 10.3390/ijms19092519. PMID: 30149619; PMCID: PMC6163214.
2: Viisanen H, Nuotio U, Kambur O, Mahato AK, Jokinen V, Lilius T, Li W, Santos HA, Karelson M, Rauhala P, Kalso E, Sidorova YA. Novel RET agonist for the treatment of experimental neuropathies. Mol Pain. 2020 Jan- Dec;16:1744806920950866. doi: 10.1177/1744806920950866. PMID: 32811276.
3: Burr DH, Rollins D, Lee LH, Pattarini DL, Walz SS, Tian JH, Pace JL, Bourgeois AL, Walker RI. Prevention of disease in ferrets fed an inactivated whole cell Campylobacter jejuni vaccine. Vaccine. 2005 Jul 29;23(34):4315-21. doi: 10.1016/j.vaccine.2005.03.038. PMID: 16005742.
4: Hickey TE, Baqar S, Bourgeois AL, Ewing CP, Guerry P. Campylobacter jejuni- stimulated secretion of interleukin-8 by INT407 cells. Infect Immun. 1999 Jan;67(1):88-93. doi: 10.1128/IAI.67.1.88-93.1999. PMID: 9864200; PMCID: PMC96281.
5: McGavock H. Strategies and tactics for effective prescribing during the foundation year. Br J Hosp Med (Lond). 2005 Aug;66(8):Suppl M3-4. doi: 10.12968/hmed.2005.66.Sup1.18523. PMID: 16097522.
